PL2481753T3 - Przeciwciała anty-IL-17 - Google Patents

Przeciwciała anty-IL-17

Info

Publication number
PL2481753T3
PL2481753T3 PL11192240T PL11192240T PL2481753T3 PL 2481753 T3 PL2481753 T3 PL 2481753T3 PL 11192240 T PL11192240 T PL 11192240T PL 11192240 T PL11192240 T PL 11192240T PL 2481753 T3 PL2481753 T3 PL 2481753T3
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL11192240T
Other languages
English (en)
Polish (pl)
Inventor
Barrett Allan
Chi-Kin Chow
Lihua Huang
Ling Liu
Jirong Lu
Kingman Ng
Jonathan Wendell Tetreault
Andrew Gordon Werner
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL2481753T3 publication Critical patent/PL2481753T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL11192240T 2005-12-13 2006-12-05 Przeciwciała anty-IL-17 PL2481753T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74995305P 2005-12-13 2005-12-13
US80194806P 2006-05-19 2006-05-19
EP06846464.3A EP1963368B3 (en) 2005-12-13 2006-12-05 Anti-il-17 antibodies
EP11192240.7A EP2481753B1 (en) 2005-12-13 2006-12-05 Anti-IL-17 Antibodies

Publications (1)

Publication Number Publication Date
PL2481753T3 true PL2481753T3 (pl) 2018-09-28

Family

ID=38008638

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06846464T PL1963368T6 (pl) 2005-12-13 2006-12-05 Przeciwciała anty-IL-17
PL11192240T PL2481753T3 (pl) 2005-12-13 2006-12-05 Przeciwciała anty-IL-17

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06846464T PL1963368T6 (pl) 2005-12-13 2006-12-05 Przeciwciała anty-IL-17

Country Status (23)

Country Link
US (2) US7838638B2 (enExample)
EP (4) EP1963368B3 (enExample)
JP (1) JP5063612B2 (enExample)
KR (1) KR101158959B1 (enExample)
CN (1) CN101326195B9 (enExample)
AU (1) AU2006325860B2 (enExample)
BR (1) BRPI0619792B1 (enExample)
CA (1) CA2631938C (enExample)
CY (3) CY1113097T1 (enExample)
DK (2) DK1963368T6 (enExample)
EA (1) EA014298B1 (enExample)
ES (2) ES2389780T7 (enExample)
HR (2) HRP20120606T4 (enExample)
HU (2) HUE039353T2 (enExample)
IL (1) IL191217A (enExample)
LT (2) LT2481753T (enExample)
LU (1) LU93189I2 (enExample)
NO (2) NO340827B1 (enExample)
PL (2) PL1963368T6 (enExample)
PT (2) PT2481753T (enExample)
RS (2) RS57255B1 (enExample)
SI (2) SI1963368T1 (enExample)
WO (1) WO2007070750A1 (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051422A1 (en) 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
EP1963368B3 (en) * 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
EP2377887A1 (en) 2006-03-10 2011-10-19 Zymogenetics Inc Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
CA2660463C (en) * 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
NZ581470A (en) 2007-06-25 2013-04-26 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
KR101573086B1 (ko) * 2007-06-25 2015-11-30 에스바테크 - 어 노바티스 컴파니 엘엘씨 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체
WO2009026412A1 (en) * 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2009245440C1 (en) 2008-05-05 2013-03-14 Novimmune Sa Anti-IL-17A/IL-17F cross-reactive antibodies and methods of use thereof
WO2010034443A1 (en) * 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
CN102369285B (zh) * 2008-11-12 2014-06-18 默沙东公司 用于增强的抗-IGF1R表达的βGl-IgG内含子
WO2010062858A1 (en) * 2008-11-26 2010-06-03 Allergan, Inc. Il-17 antibody inhibitor for treating dry eye
US8211434B2 (en) * 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
RU2015132478A (ru) * 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
AU2010244142B2 (en) 2009-05-05 2016-07-21 Novimmune Sa Anti-IL-17F antibodies and methods of use thereof
KR101836217B1 (ko) 2009-10-30 2018-03-08 얀센 바이오테크 인코포레이티드 Ｉｌ-１７ａ 길항제
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
NZ607615A (en) 2010-08-05 2015-03-27 Anaptysbio Inc Antibodies directed against il-17
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
LT2625199T (lt) * 2010-10-08 2018-03-12 Novartis Ag Psoriazės gydymo būdai panaudojant il-17 antagonistus
US20230227427A1 (en) 2010-10-26 2023-07-20 Sanofi Il-17a modulators
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
MY162790A (en) 2011-01-14 2017-07-14 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US20150064193A1 (en) 2011-11-21 2015-03-05 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
PT2822590T (pt) 2012-03-07 2016-12-15 Lilly Co Eli Formulação de anticorpo de il-17
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US20150125462A1 (en) 2012-04-20 2015-05-07 Stephan Bek Methods of treating ankylosing spondylitis using il-17 antagonists
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
KR20150088853A (ko) 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
SG11201505330QA (en) 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20150004133A1 (en) * 2013-06-07 2015-01-01 The Regents Of The University Of California Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP3033107A1 (en) 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
CA2929662C (en) * 2013-11-18 2023-05-02 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
KR102056963B1 (ko) 2013-12-30 2019-12-17 에피맙 바이오테라퓨틱스 인코포레이티드 Fabs-인-탠덤 면역글로불린 및 이의 용도
EP3107574A2 (en) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispecific antibodies and uses thereof
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
DK3191120T3 (da) 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR20240110106A (ko) 2015-01-12 2024-07-12 애피바디 에이비 Il-17a-결합 폴리펩티드
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
MA42444A (fr) 2015-07-16 2018-05-23 Lilly Co Eli Traitement du prurit
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
EP4477265A3 (en) 2016-07-19 2025-03-19 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
BR112019004990A2 (pt) * 2016-09-14 2019-06-04 Beijing hanmi pharm co ltd anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
AU2018217816A1 (en) 2017-02-10 2019-08-15 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
US10858427B2 (en) 2017-03-10 2020-12-08 Suzhou Kanova Biopharmaceutical Co., Ltd. Monoclonal antibody against both IL-17A and IL-17F and use of the same
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CA3065553A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. Il17a antibodies and antagonists for veterinary use
WO2019027828A1 (en) 2017-08-04 2019-02-07 Eli Lilly And Company DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
WO2019040230A1 (en) 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
US20210179702A1 (en) 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
WO2019091449A1 (zh) * 2017-11-10 2019-05-16 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
KR102048475B1 (ko) * 2017-11-10 2019-11-26 주식회사 와이바이오로직스 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
AU2018375738A1 (en) 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN112074541A (zh) 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
EP3816184B1 (en) 2018-05-17 2023-04-26 Jiangsu Qyuns Therapeutics Co., Ltd. Anti-human interleukin 17a monoclonal antibody and application thereof
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
JP7504871B2 (ja) 2018-08-29 2024-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 関節リウマチを有する対象を治療するための方法および組成物
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN111018974B (zh) * 2018-10-10 2022-04-01 东莞市朋志生物科技有限公司 一种抗人心肌肌钙蛋白i的重组抗体
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
CN109369806B (zh) * 2019-01-14 2019-04-19 迈威(上海)生物科技有限公司 苏金单抗制品中半胱氨酸化变异体的去除方法
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
US12503505B2 (en) 2019-01-31 2025-12-23 Numab Therapeutics AG Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
EP3959240A1 (en) 2019-04-24 2022-03-02 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
KR102400401B1 (ko) * 2019-05-22 2022-05-24 (주)셀인바이오 항염증 펩타이드 및 항염증 조성물
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7214921B2 (ja) 2019-07-26 2023-01-30 神州細胞工程有限公司 ヒト化抗ｉｌ１７ａ抗体及びその使用
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
KR20220103141A (ko) 2019-11-19 2022-07-21 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용하여 루푸스 신장염을 치료하는 방법
CA3162052A1 (en) 2019-12-06 2021-06-10 Novartis Ag Methods of treating lichen planus using interleukin-17 (il-17) antagonists
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
EP4077349A1 (en) 2019-12-16 2022-10-26 BicycleTX Limited Bicyclic peptide ligands specific for il-17
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
BR112022023983A2 (pt) 2020-05-27 2022-12-20 Sanofi Sa Compostos terapêuticos
KR20230025890A (ko) 2020-06-23 2023-02-23 노파르티스 아게 인터루킨-17(il-17) 길항제를 이용한 갑상선 안병증 및 그레이브스 안와병증의 치료 방법
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
CN115746132B (zh) * 2021-09-03 2023-09-08 三优生物医药(上海)有限公司 抗il-17a抗体及其用途
IT202100023816A1 (it) * 2021-09-16 2023-03-16 Takis S R L Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
CN113896793B (zh) * 2021-09-30 2023-05-26 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用
CN119630422A (zh) 2022-05-16 2025-03-14 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
WO2024121427A1 (en) 2022-12-09 2024-06-13 Sanofi Therapeutic compounds
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025104230A1 (en) 2023-11-17 2025-05-22 Sanofi Benzoxazoles as modulators of il-17a
WO2025248073A1 (en) 2024-05-30 2025-12-04 Sanofi Therapeutic compounds
CN120249218A (zh) * 2024-10-15 2025-07-04 武汉纺织大学 一种分泌抗微纳塑料广谱性单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US539A (en) 1837-12-26 Standard measurer for taking measure for coats
US5225A (en) 1847-08-07 Latch
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005051422A1 (en) 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) * 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies

Also Published As

Publication number Publication date
US20080269467A1 (en) 2008-10-30
CY1113097T1 (el) 2016-04-13
HRP20180941T1 (hr) 2018-08-10
CN101326195B9 (zh) 2022-11-11
EA014298B1 (ru) 2010-10-29
NO340827B1 (no) 2017-06-26
CN101326195B (zh) 2012-01-11
LU93189I2 (fr) 2016-10-31
NO20082905L (no) 2008-09-03
BRPI0619792B1 (pt) 2021-09-28
PL1963368T3 (pl) 2012-11-30
RS52509B (sr) 2013-04-30
US8110191B2 (en) 2012-02-07
EP2481753A1 (en) 2012-08-01
US7838638B2 (en) 2010-11-23
CA2631938A1 (en) 2007-06-21
NO2017044I1 (no) 2017-08-18
PT1963368E (pt) 2012-09-14
AU2006325860B2 (en) 2011-09-22
EA200870050A1 (ru) 2009-12-30
EP2481753B1 (en) 2018-04-18
KR20080068122A (ko) 2008-07-22
HK1120275A1 (en) 2009-03-27
CY1120365T1 (el) 2019-07-10
HUE039353T2 (hu) 2018-12-28
PL1963368T6 (pl) 2021-02-08
RS52509B2 (sr) 2020-09-30
WO2007070750A1 (en) 2007-06-21
ES2672221T3 (es) 2018-06-13
RS57255B1 (sr) 2018-08-31
LTPA2016026I1 (lt) 2016-09-26
HUS1600037I1 (hu) 2016-10-28
CY2016030I2 (el) 2016-12-14
KR101158959B1 (ko) 2012-07-09
HRP20120606T4 (hr) 2020-08-07
EP3366702A1 (en) 2018-08-29
LT2481753T (lt) 2018-05-25
DK2481753T3 (en) 2018-06-18
SI1963368T1 (sl) 2012-11-30
EP1963368A1 (en) 2008-09-03
DK1963368T3 (da) 2012-08-06
EP3366702B1 (en) 2023-08-09
CA2631938C (en) 2014-05-20
US20110027290A1 (en) 2011-02-03
LTC1963368I2 (lt) 2018-01-10
ES2389780T7 (es) 2021-01-14
EP1963368B1 (en) 2012-07-18
EP3808769A1 (en) 2021-04-21
DK1963368T6 (da) 2020-06-29
ES2389780T3 (es) 2012-10-31
EP1963368B3 (en) 2020-06-10
NO2017044I2 (no) 2017-08-18
SI2481753T1 (en) 2018-06-29
BRPI0619792A2 (pt) 2011-10-18
JP2009519348A (ja) 2009-05-14
AU2006325860A1 (en) 2007-06-21
JP5063612B2 (ja) 2012-10-31
PT2481753T (pt) 2018-07-13
CN101326195A (zh) 2008-12-17
IL191217A (en) 2015-10-29
CY2016030I1 (el) 2016-12-14
HRP20120606T1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
HUS1600037I1 (hu) Anti-IL-17 ellenanyagok
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
ZA200805850B (en) Anti-ILT7 antibody
IL181575A0 (en) Anti-ox40l antibodies
IL185366A0 (en) Antibody
IL228032A0 (en) Antibodies
GB0420466D0 (en) Anti-glucan antibodies
GB0517487D0 (en) Antibodies
ZA200701952B (en) Anti-OX40L antibodies
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB0505489D0 (en) Antibodies
GB0418415D0 (en) Antibody
GB0505054D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0420771D0 (en) Antibody
GB0519883D0 (en) Antibodies
GB0500400D0 (en) Antibody
GB0402642D0 (en) Antibodies
GB0402641D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies